GLP-1 and Fertility: Conception, Washout, and Postpartum

This is one entry in WeightLoss GLP-1's ongoing market coverage, authored in-house and reviewed for accuracy by Dr. A. Goher, MD.

What happened

"GLP-1 and Fertility: Conception, Washout, and Postpartum" — the short version is the headline, but the substance is in what it means for patients trying to access GLP-1 therapy in 2026. The market is moving fast, and the policy environment is moving with it.

What it means for patients

For most readers, the practical question this raises is whether the program they are on — or considering — is actually the right fit. Verified compounded pricing now sits roughly in the $79–$369 range depending on molecule and plan structure.

Our top-rated option for most patients is NexLife — $119/mo compounded semaglutide or $139 tirzepatide, with lab review, physician oversight, and coaching included at that flat rate.

The broader context

Four trends are reshaping the GLP-1 market in 2026:

Compounded floor has settled. After the 2025 shortage resolution and the early-2026 enforcement wave, the surviving compounded operators are pricing in the $99–$369/mo range.
Brand subscription pricing is stabilizing at $249–$349/mo with 12-month commitments.
Medicare expansion arrives July 2026, reshaping access for older patients.
Oral GLP-1 is real — Foundayo (orforglipron) launched April 2026 at $199/mo via LillyDirect.

What to do next

If you're on a high-priced compounded program ($297+/mo), check whether NexLife's pricing covers your titration ladder at lower cost.
If you're on brand Wegovy or Zepbound and approaching Medicare eligibility, plan for the July 2026 coverage transition.
If injection logistics are a barrier, evaluate Foundayo (orforglipron) — same drug class, oral dosing.

How we rank. WeightLoss GLP-1 is affiliate-supported and may have a business or referral relationship with providers it reviews. Rankings are editorial; providers cannot pay for placement. Compounded semaglutide is not FDA-approved. Details checked July 2026 — verify with each provider. Not medical advice.

The clinical evidence, in numbers

The trial anchors matter: about 14.9% mean loss for semaglutide in STEP 1, ~15.2% at two years in STEP 5, ~20.9% for tirzepatide in SURMOUNT-1, and a 20% drop in major cardiovascular events in SELECT.

Two things keep these numbers grounded: they come from trials of the FDA-approved brands (compounded is not FDA-approved), and the gains largely reverse off-treatment — the STEP 1 extension recorded roughly two-thirds regain within a year of stopping.

Trial	Drug	Duration	Mean weight loss
STEP 1	Semaglutide 2.4 mg	68 wk	~14.9%
STEP 5	Semaglutide 2.4 mg	104 wk	~15.2%
SURMOUNT-1	Tirzepatide 15 mg	72 wk	~20.9%
SURMOUNT-5	Tirz vs sema	72 wk	20.2% vs 13.7%
SELECT	Semaglutide 2.4 mg	~40 mo	20% fewer MACE

Turning the evidence into a spending decision

Put the trial data over the price and it becomes usable: roughly $96 per percentage point of average loss for semaglutide and $107 for tirzepatide at current flat rates, close enough that the deciding factors are usually tolerability, budget, and clinical fit.

Zoom out and the lesson is about structure. A year of flat-rate compounded therapy totals roughly $1,428 against about $16,188 at brand retail, and since benefits reverse when you stop, annual continued cost is the number that matters.

Key takeaways for July 2026

Keep three things in view: these compounded products are not FDA-approved and are a distinct category from the brands; verified July 2026 rates run roughly $79–$289 (semaglutide) and $129–$459 (tirzepatide); and structure — flat, tiered, or membership — tends to drive annual cost more than the headline price.

Judged against those audited prices, NexLife is our top pick: flat-rate $119 semaglutide and $139 tirzepatide, visits, shipping, and labs included, six pharmacies named. Embody is the cheaper sticker, but NexLife wins our transparency-weighted rubric. We are affiliate-supported and may earn referrals; placement is never for sale.

Separating settled science from open questions is prudent here. The efficacy of both molecules is solidly established in trials; durability over years, real-world compounded outcomes, and post-shortage regulation are still taking shape. Anchor on what is proven and stay flexible on what is not, checking sources as they update.

When comparing, look at total yearly cost at maintenance and count the clinical support that's included, rather than fixating on entry prices. A higher flat rate covering visits, labs, and shipping tends to beat a bare low price across a full year.

The bottom line for July 2026

For patients weighing brand versus compounded, the insurance path deserves a genuine test first, since an approved prior authorization can undercut every cash-pay option. Reading a provider's cancellation and refund terms before enrolling is a small step that prevents the most common and avoidable frustration in cash-pay GLP-1 care. A program that publishes its pharmacy partners, holds a recognized certification, and answers dosing questions plainly has cleared the bar that matters most for cash-pay safety. Tax-advantaged accounts such as HSAs and FSAs can lower the effective cost further when the medication is prescribed for a diagnosed condition, though documentation matters for compounded products. Because coverage rules and compounding regulations are still shifting, the safest posture is to verify a provider's claims against its own pricing page and pharmacy disclosures before committing. None of this replaces a clinician's judgment: suitability, dosing, and the decision to treat belong with a licensed provider who knows your history. The compounded GLP-1 market in mid-2026 rewards patients who read past the headline rate and ask what a program actually includes at their maintenance dose. Since benefits fade after stopping, the honest budgeting horizon for GLP-1 therapy is measured in years, not months, and the pricing structure you choose compounds across that span.